Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 6Rhabdomyosarcoma 5Sarcoma, Synovial 3Osteosarcoma 3Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Wilms Tumor 1Retinoblastoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Malignant mesenchymal tumor 1Histiocytoma, Malignant Fibrous 1Hepatoblastoma 1Hemangiopericytoma, Malignant 1Desmoplastic Small Round Cell Tumor 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1Adrenocortical Carcinoma 1

Interventions

Filgrastim 10Cyclophosphamide 8X-Rays 6Phantoms, Imaging 6Granulocyte Colony-Stimulating Factor 6Temozolomide 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Ifosfamide 5Carboplatin 5Vincristine 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Melphalan 4Etoposide 4Busulfan 4Topotecan 3Thiotepa 3Stem Cell Transplantation 3Mesna 3Cisplatin 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × cixutumumab × Sarcoma × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡